Terbinafine topical

Drug Profile

Terbinafine topical

Alternative Names: MOB-015; MOB015B

Latest Information Update: 14 Oct 2016

Price : $50

At a glance

  • Originator Moberg Derma
  • Developer Moberg Pharma
  • Class Antifungals; Naphthalenes; Small molecules
  • Mechanism of Action Cell membrane modulators; Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Onychomycosis

Highest Development Phases

  • Phase III Onychomycosis

Most Recent Events

  • 01 Sep 2016 Phase-III clinical trials in Onychomycosis (In adolescents, In adults, In the elderly) in USA and Canada (Topical) (NCT02859519)
  • 01 Sep 2016 Phase-III clinical trials in Onychomycosis (In adults, In the elderly) in Germany (Topical) (NCT02866032)
  • 26 Aug 2016 Moberg plans a phase III trial for Onchomycosis in Poland and Germany (Topical) (NCT02866032)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top